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Although Vaccinia virus (VACV) was used to eradicate smallpox by dermal vaccination, there is
little information available about the immune response induced at the vaccination site. Previously,
an intradermal murine model that mimics smallpox vaccination was established. Here, this model
was used to investigate which leukocytes are recruited to the infected lesion and what are the
kinetics of recruitment. Data presented show that VACV infection induced the infiltration of
macrophages, followed by granulocytes and lymphocytes. Up to 4 days post-infection, the major
lymphocyte population was TCRcd T cells, but thereafter, there was a large recruitment of CD4+
and CD8+ T cells. Interestingly, the majority of T cells expressed the natural killer-cell marker
DX5. This report is the first to characterize the local immune response sequence to VACV infection
and represents a benchmark against which the responses induced by genetically modified
VACVs may be compared.
Vaccinia virus (VACV) is a potent vaccine against smallpox,
but its use was discontinued in the 1970s following smallpox
eradication. Recently, vaccination of limited numbers of
health-care workers was introduced in the USA, the UK and
elsewhere in response to a perceived threat of bioterrorism
withVariola virus, the aetiological agent of smallpox. Despite
worldwide use of VACV as the smallpox vaccine, only recently
have studies analysed the systemic immune response induced
in animals (Belyakov et al., 2003; Earl et al., 2004; Xu et al.,
2004) and humans (Crotty et al., 2003; Frey et al., 2003;
Hammarlund et al., 2003; Amara et al., 2004; Belshe et al.,
2004; Combadiere et al., 2004; Greenberg et al., 2005; Pu¨tz
et al., 2005; Rock et al., 2005) by modern immunological
techniques. However, the immune response at the vaccination
site remains poorly understood.
Previously, an intradermal model in the mouse ear pinnae
that mimics dermal vaccination with VACV was developed
(Tscharke & Smith, 1999). Following vaccination, no signs
of systemic illness were observed and there was little or no
virus spread from the ear. Subsequently, this model was used
to assess virulence of different strains of VACV, other
orthopoxviruses and VACV mutants engineered to lack
specific virus genes (Tscharke et al., 2002). Fig. 1(a) shows
that this vaccination induced protection against challenge
with all doses of VACV strain Western Reserve (WR) tested
(up to 107 p.f.u.). It was established previously that doses of
105 p.f.u. or greater are lethal in this model (Wilcock et al.,
1999; Symons et al., 2002; Fogg et al., 2004; Davies et al.,
2005). Another report analysed cells that had infiltrated into
VACV-infected ears by separation of the ventral and the
dorsal dermal sheets and incubation of these on culture
medium at 37 uC for 8–10 h (Reading & Smith, 2003). Non-
adherent cells that had migrated from the dermal layers were
pooled with the loosely adherent cells recovered by a further
incubation (20 min) in PBS containing glucose (2 mg ml21),
but without calcium and magnesium. With this technique,
called the ‘migration technique’, only up to 100 000 cells
were isolated per mock-infected ear or ear early post-
infection (p.i.) (Reading & Smith, 2003) (Fig. 1b), making
analysis of the leukocyte population difficult. For example,
lymphocyte subsets were able to be characterized only after
day 7 p.i. (Reading & Smith, 2003). To increase the number
of cells isolated from infected ears in order to permit more
extensive lymphocyte characterization, we tried enzymic
digestion with trypsin, collagenase or liberase and compared
cells obtained by these methods with those obtained by
migration.
The intradermal model was established with BALB/c mice
infected with 104 p.f.u. VACV (strain WR) (Tscharke &
Smith, 1999), but lesions are bigger in C57BL/6 mice
(Tscharke et al., 2002) and therefore most of the experi-
ments were undertaken with this strain. For enzymic diges-
tions, the ventral and dorsal dermal sheets were separated by
using forceps and incubated with collagenase (Sigma, crude
type XI collagenase; 1 mg ml21, 75 min at 37 uC) (Belkaid
et al., 1996), trypsin (Invitrogen; 0?5–1?0 %, 30 min at 37 uC)
(Belkaid et al., 1998) or liberase CI (Sigma; 50 mg ml21,
40 min at 37 uC) (Hawlisch et al., 2005); cells were then
filtered by using a 70 mm nylon cell strainer (Becton
Dickinson). Cell numbers obtained with trypsin or
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collagenase were similar and twofold higher than those
obtained with liberase (data not shown). However, trypsin
treatment removed some cell-surface markers (i.e. CD4
and CD8) that were recovered after 2–4 h incubation at
37 uC (data not shown). Liberase digestion produced fewer
contaminating endothelial or epithelial cells, but preferen-
tially isolated lymphocytes and, to a lesser extent, macro-
phages and granulocytes (data not shown). Therefore, to
enable analysis of all leukocyte populations and to avoid the
problem of trypsin digestion, we selected collagenase
treatment for our study.
Fig. 1(b) shows the number of cells obtained with migration
or collagenase techniques after VACV infection. In mock-
infected ears and up to 8 days p.i., there was an increase of
>10-fold in cell recovery using collagenase digestion com-
pared with migration and the biggest difference was on day
2 p.i. (>50-fold). Collagenase treatment yielded more than
106 cells per ear for each time point and this was sufficient
for phenotypic analysis of the cells. Interestingly, the number
of cells recovered by collagenase treatment dropped at day
11 p.i., whereas by using the migration technique, more cells
were recovered at this time than earlier (Fig. 1b). Previous
results using migration showed an increase in cell number,
even at day 15 p.i. (Reading & Smith, 2003), when the lesion
size had decreased, and immunohistochemical detection of
VACV with an antibody against the B5R protein was very
weak at days 10 and 12 p.i.
Although <30 % of total cells recovered from mock-
infected ears by collagenase treatment were leukocytes
[detected by CD45 mAb–fluorescein isothiocyanate (FITC);
Serotec], compared with around 80 % with the migration
technique, the total numbers of macrophages and lympho-
cytes were >50- and >60-fold-increased with enzymic
digestion (Fig. 1c). At day 5 p.i., leukocytes (CD45+)
represented 70–90 % of total cells recovered with either
technique (data not shown). In addition to different num-
bers of cells being recovered by the two techniques, the cells
recovered showed different kinetics of infiltration in the
ears. With collagenase treatment, macrophages, which play
an important role in the innate response and were detected
with F4/80–Tri-Color mAb (Caltag), peaked at day 5 and
then declined to levels found in mock-infected ears by day
11. Similarly, effectors of the adaptive immune response,
such as T cells [detected with anti-CD3–phycoerythrin
(PE)–Cy5 mAb; BD Pharmingen], recovered by collagenase
treatment, peaked at day 8 and then declined. In contrast,
with migration, both macrophages and T cells were maximal
at day 11 (Fig. 1c). Similar results were observed with the
BALB/c mouse strain (data not shown). Isolation of leuko-
cytes by collagenase treatment enabled the beginning and
end of the immune innate response and the subsequent
adaptive response to be followed. Moreover, when cells
were isolated by collagenase treatment, the kinetics of cell
infiltration followed the kinetics of the innate and adaptive
immune response more closely. In contrast, the immune-
cell infiltration observed with the migration technique
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Fig. 1. (a) Weight loss of groups (n=2–5) of BALB/c mice
infected intranasally with the indicated doses of VACV WR or
mock-infected. Twenty-eight days after intradermal immunization
or not (‘No immuni.’ group) with 104 p.f.u. VACV strain WR in
both ears, the mice were challenged intranasally and weighed
daily. (b, c) Cell isolation by migration and collagenase techni-
ques after intradermal infection of C57BL/6 mice with 104 p.f.u.
VACV WR. (b) Total numbers of viable cells as determined by
trypan blue exclusion. (c) Total number of T cells (CD3) and
macrophages (MØ) obtained with migration (‘migr’) or colla-
genase (‘coll’) techniques. Data are means±SEM of cell count
by ear (n¢6 except for mock-infected ear with migration tech-
nique, where n=1).
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continued even after the lesion had healed (Tscharke et al.,
2002). These results suggested that the collagenase technique
is more appropriate than the migration technique to study
the kinetics of leukocyte populations after viral infection,
and the large number of cells obtained enabled functional
analyses of these cells.
Leukocyte populations present in the VACV-infected ear
and obtained with the collagenase technique were analysed
further (Fig. 2). Resident macrophages constituted the
major subpopulation of leukocytes in the mock-infected
ear and early after VACV infection (Fig. 2a, b), as reported
previously by in situ analysis of the mouse ear dermis
(Dupasquier et al., 2004). However, later after infection, the
percentage of macrophages decreased (Fig. 2a) and their
absolute number declined after day 4 p.i. (Fig. 2b). The
proportion of granulocytes (detected by high expression of
Ly6G–PE; BD Pharmingen) increased slightly by day 2 p.i.
(Fig. 2a) and continued to increase up to day 10 p.i.,
followed by a decline. The percentage of lymphocytes
continued to increase up to day 17 p.i. (Fig. 2a), when the
lesions had mostly disappeared and most leukocytes were
lymphocytes (Fig. 2a, b). To detect antigen-presenting cells
(APCs), cells were stained with anti-CD11c–PE and anti-
major histocompatibility complex class II mAb–FITC (BD
Pharmingen), which recognize both dermal dendritic cells
and Langerhans cells. The number of these cells increased
only slightly after infection and the proportion of APCs
was similar to the percentage found in situ in mouse ear
(Dupasquier et al., 2004). Overall, these data suggest that
collagenase treatment enabled the kinetic response of the
different immune populations to be evaluated after viral
infection.
Further analysis of lymphocyte subsets studied recruitment
of CD4+, CD8+, natural killer (NK) and TCRcd cells
(Fig. 2c, d). Among the T cells, TCRcd cells are abundant in
murine skin (Asarnow et al., 1988). These cells are con-
sidered a first line of defence and play a role in the control of
viral infection (Ninomiya et al., 2000; Wang et al., 2003),
including after intraperitoneal infection with VACV (Selin
et al., 2001). Up to day 4, these cells (detected with anti-
TCRcd–PE mAb; BD Pharmingen) were the major popula-
tion of lymphocytes (Fig. 2c, d). Previously, the lymphocyte
populations have been studied only after day 7 p.i., due to
the limited number of cells obtained, and TCRcd T cells were
a minor population in the VACV-infected ear (Reading &
Smith, 2003). The percentage of these cells did not increase
after VACV infection (Fig. 2d), but the absolute cell number
increased up to day 4 p.i.
NK cells are another effector population of the innate
response that was reported to be involved in the response
to VACV infection (Bukowski et al., 1983; Kennedy et al.,
2000), but few studies have addressed NK recruitment after
VACV infection (Natuk & Welsh, 1987; Prlic et al., 2005). In
this study, usually <1 % of lymphocytes in mock-infected
ears were NK cells (detected with NK1.1–FITC mAb; BD
Pharmingen) (data not shown), but the percentage and
absolute number of NK cells increased and peaked at day
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Fig. 2. Percentages and total numbers of
different leukocyte populations present in
VACV-infected ears at different times p.i. (a,
c) Percentage and (b, d) total cell number
by ear of (a, b) lymphocytes, granulocytes,
dendritic cells and macrophages in leukocyte
gate, and (c, d) NK, TCRcd, CD8+ and
CD4+ cells in lymphocyte gate. Data are
means±SEM (n¢6).
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7–10 p.i. NK activity against K562 target cells, detected with
a 51Cr-release assay, was observed 6 days p.i. (data not
shown). The changes in the numbers of TCRcd and NK cells
were not described previously because these lymphocyte
populations were followed only after day 7 p.i. (Reading &
Smith, 2003), by when these cell populations had already
decreased (Fig. 2c, d).
Compared with other lymphocytes, the infiltration of cells
from the adaptive immune response, such as CD4+ and
CD8+ T cells, was later and more pronounced, especially on
day 7–10 p.i. (Fig. 2c, d). The percentage of CD4+ T cells
(detected with anti-CD4–Tri-Color mAb; Caltag) still
increased at day 17 p.i. (Fig. 2c), whereas the majority of
the lesions had resolved at that time. In contrast, the
percentage of CD8+ T cells (detected with anti-CD8–PE–
Cy5 mAb; BD Pharmingen) decreased after day 7 p.i.
(Fig. 2c). The absolute number of both T-cell subsets
declined after day 10 p.i. (Fig. 2d). Cytotoxic T-lymphocyte
activity against EL4 cells infected at 10 p.f.u. per cell with
VACV strain WR was detected by using a 51Cr-release assay
by day 7 p.i. (data not shown), as reported with BALB/c
mice (Reading & Smith, 2003). Depletion of lymphocyte
subsets showed that both CD4+ and CD8+ T cell-mediated
immunity contributes to protection against intraperitoneal
infection with VACV (Xu et al., 2004).
An expansion of T cells expressing NK-cell markers was
reported in the lungs of influenza virus-infected mice
(Kambayashi et al., 2001) and in the spleen of lymphocytic
choriomeningitis virus-infected mice (Slifka et al., 2000).
These cells are usually referred to as ‘NKT cells’. The pro-
portion of T cells expressing NK1.1, used to quantify the NK
cells, was very low (<1 %) in mock-infected ears and did
not increase after VACV infection (data not shown). The
presence of another NK-cell marker, DX5, which is also
expressed on all murine NK cells, was detected on only a
few CD3+ T cells in mock-infected ears (Fig. 3a) and the
majority of these cells co-expressed NK1.1 (data not shown).
However, during VACV infection, a population of T cells
expressing DX5 (but not NK1.1) emerged (Fig. 3a, b) and
underwent enormous expansion (>400-fold) that was the
highest among all of the cell populations studied (Fig. 3b).
At day 9 p.i., 67±7 % of these DX5+CD3+ cells were CD4+
and 28±7 % were CD8+ (data not shown). After day 10 p.i.,
the percentage and number of these cells decreased (Fig. 3b)
in parallel with the reduction in lesion size (Tscharke et al.,
2002). CD3+DX5+ T cells were associated with activation
marker (CD69) and subsequent cell death in influenza virus
infection (Kambayashi et al., 2001) and the results presented
here suggest that NKT cells could play an important role in
the control of VACV infection.
VACV was used to eradicate smallpox, and VACV recom-
binants expressing foreign antigens were proposed as vac-
cines against other infectious diseases (Smith et al., 1983).
The intradermal ear-infection model mimics dermal
vaccination because only a local lesion develops (Tscharke
& Smith, 1999) and immunity against VACV challenge is
induced (Fig. 1a). In this report, the different leukocyte
populations infiltrating into the VACV-infected ear are
described. VACV encodes numerous proteins that interfere
with the host response to infection (Smith et al., 1997; Moss
& Shisler, 2001) and their study is relevant to the develop-
ment of recombinant VACV vaccines. The local immune
response reported here could be used as a reference to test
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Fig. 3. Percentage and number of T cells
expressing DX5. (a) Fluorescence-associated
cell-sorting dot plot showing CD3+ versus
DX5+ staining in mock-infected ears on
days 7 and 10 p.i. (b) Percentage and cell
number by ear of T cells expressing DX5.
Data are means±SEM (n¢6).
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the effects of these different immunomodulatory proteins.
Moreover, this intradermal model could be suitable to study
the kinetics of the immune response in other viral infections.
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